Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
Humacyte announced that the Israeli Ministry of Health has accepted their Marketing Authorization Application for Symvess® (acellular tissue engineered vessel) to treat vascular trauma. The ministry has assigned a 180-working-day review period. This acceptance marks an important step in the company's plan to expand Symvess beyond the U.S., leveragi…